Edwards Lifesciences Corporation (NYSE:EW) – Leerink Swann decreased their FY2017 EPS estimates for shares of Edwards Lifesciences Corporation in a research note issued to investors on Tuesday. Leerink Swann analyst D. Antalffy now expects that the medical research company will post earnings per share of $3.74 for the year, down from their previous estimate of $3.75. Leerink Swann also issued estimates for Edwards Lifesciences Corporation’s FY2018 earnings at $3.94 EPS.

A number of other research firms have also weighed in on EW. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a research note on Tuesday, July 18th. SunTrust Banks, Inc. upped their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Jefferies Group LLC upped their price objective on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $120.75.

WARNING: “Leerink Swann Analysts Lower Earnings Estimates for Edwards Lifesciences Corporation (EW)” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/13/leerink-swann-analysts-lower-earnings-estimates-for-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation (NYSE:EW) opened at 110.20 on Friday. The company has a market capitalization of $23.42 billion, a price-to-earnings ratio of 42.22 and a beta of 0.62. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45. The company has a 50 day moving average of $111.51 and a 200 day moving average of $111.23.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the business earned $0.76 EPS.

A number of large investors have recently modified their holdings of EW. Teachers Advisors LLC increased its holdings in Edwards Lifesciences Corporation by 26.6% in the 1st quarter. Teachers Advisors LLC now owns 835,393 shares of the medical research company’s stock worth $78,585,000 after buying an additional 175,457 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Edwards Lifesciences Corporation by 32.3% in the 1st quarter. TIAA CREF Investment Management LLC now owns 1,717,227 shares of the medical research company’s stock worth $161,540,000 after buying an additional 419,266 shares during the period. Bridgewater Associates LP acquired a new position in Edwards Lifesciences Corporation in the 1st quarter worth approximately $4,272,000. California Public Employees Retirement System increased its holdings in Edwards Lifesciences Corporation by 1.8% in the 1st quarter. California Public Employees Retirement System now owns 459,900 shares of the medical research company’s stock worth $43,263,000 after buying an additional 8,200 shares during the period. Finally, FDO Partners LLC increased its holdings in Edwards Lifesciences Corporation by 131.8% in the 1st quarter. FDO Partners LLC now owns 43,261 shares of the medical research company’s stock worth $4,070,000 after buying an additional 24,594 shares during the period. Institutional investors own 82.12% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $114.68, for a total value of $607,804.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 182,201 shares of company stock worth $20,768,154. Corporate insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.